AZD 3778
Alternative Names: AZD3778Latest Information Update: 28 Jun 2006
At a glance
- Originator AstraZeneca
- Class Antiasthmatics
- Mechanism of Action Chemokine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Rhinitis
Most Recent Events
- 08 Jun 2006 Discontinued - Phase-II for Rhinitis in United Kingdom (unspecified route)
- 02 Feb 2006 Phase-II clinical trials in Rhinitis in United Kingdom (unspecified route)
- 14 Oct 2004 Phase-I clinical trials in Asthma in United Kingdom (unspecified route)